EP3645750A1 - Bacillus pumilus - Google Patents

Bacillus pumilus

Info

Publication number
EP3645750A1
EP3645750A1 EP18733289.5A EP18733289A EP3645750A1 EP 3645750 A1 EP3645750 A1 EP 3645750A1 EP 18733289 A EP18733289 A EP 18733289A EP 3645750 A1 EP3645750 A1 EP 3645750A1
Authority
EP
European Patent Office
Prior art keywords
strain
animals
dsm
preparation
pumilus strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18733289.5A
Other languages
English (en)
French (fr)
Inventor
Stefan Pelzer
Daniel Petri
Christos GIATSIS
Stella Molck
Maike KIPKER
Jessica KLEINBÖLTING
Lorena STANNEK-GÖBEL
Kiran DORANALLI
John Khun Kyaw HTOO
Claudia BORGMEIER
Sandra HERBOLD
Guido Meurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAIN Biotech AG
Original Assignee
Evonik Operations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations GmbH filed Critical Evonik Operations GmbH
Publication of EP3645750A1 publication Critical patent/EP3645750A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A01N63/22—Bacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F11/00—Treatment of sludge; Devices therefor
    • C02F11/02—Biological treatment
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F3/00—Biological treatment of water, waste water, or sewage
    • C02F3/34—Biological treatment of water, waste water, or sewage characterised by the microorganisms used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/20—Nature of the water, waste water, sewage or sludge to be treated from animal husbandry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus

Definitions

  • Bacillus pumilus strain with probiotic activity The current invention concerns a new B. pumilus strain with strong inhibition of swine and poultry related pathogens and its use as probiotic.
  • probiotics also called “direct- fed microbials” or “DFM”
  • DFM direct- fed microbials
  • AGPs antibiotic growth promotors
  • the bacteria according to the current invention exhibit many advantageous features. Besides their ability to inhibit growth of C. perfringens, C. difficile, S. aureus subsp. aureus, S. gallinaceus, S. suis and E. cecorum, the main commercially relevant pathogens of swine and poultry, they in particular show a very high proliferation rate in presence of bile and help to digest cellulose in a very effective way.
  • Bacillus pumilus DSM 32539 has been identified by targeted screening of naturally occurring isolates. It has been deposited with the DSMZ on June 14, 2017 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Degussa GmbH.
  • a first subject of the current invention is a Bacillus pumilus strain and/or a preparation of said Bacillus pumilus strain selected from the following group:
  • a mutant of the Bacillus pumilus strain as deposited under DSM 32539 having all identifying characteristics of the strain DSM 32539 wherein said mutant preferably has a DNA sequence identity to the strain DSM 32539 of at least 95%, preferably at least 96, 97 or 98 %, more preferably at least 99, 99.5 or 99.8 % and/or wherein that mutant preferably has a genomic DNA sequence identity to the strain DSM 32539 of at least 95 %, preferably at least 96, 97 or 98 %, more preferably at least 99, 99.5 or 99.8 %, in particular of 100 %;
  • yqfD sequence with a sequence identity of at least 99 or 99.5 %, in particular 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;
  • gyrB sequence with a sequence identity of at least 99 or 99.5 %, in particular 100 %, to the polynucleotide sequence according to SEQ ID NO: 3;
  • an rpoB sequence with a sequence identity of at least 99 or 99.5 %, in particular 100 %, to the polynucleotide sequence according to SEQ ID NO: 4;
  • a further subject of the current invention is a Bacillus pumilus strain, in particular a B. pumilus strain with the characteristics as mentioned before, or a preparation thereof, wherein the B. pumilus strain exhibits at least one, preferably all, of the following characteristics:
  • a yqfD sequence with a sequence identity of at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;
  • gyrB sequence with a sequence identity of at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 3;
  • groEL sequence with a sequence identity of at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5;
  • B. pumilus strain further preferably exhibits a 16S rDNA sequence with a sequence identity of at least 99 %, more preferably at least 99.5, 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 1.
  • a further subject of the current invention is also a Bacillus pumilus strain or a preparation thereof, in particular a B. pumilus strain with the characteristics as mentioned before, exhibiting two, three or four, more preferably all, of the following characteristics:
  • a 16S rDNA sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 1;
  • a yqfD sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;
  • a gyrB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 3;
  • an rpoB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 4;
  • groEL sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5.
  • a particular subject of the current invention is also a Bacillus pumilus strain, exhibiting the following characteristics:
  • this B. pumilus strain exhibits the following further characteristics:
  • strains of the current invention are preferably characterized by at least one, more preferably by all, of the following further features: They are preferably able to grow under anaerobic conditions. Further, they are preferably able to degrade water-insoluble cellulose as well as protein under such anaerobic conditions.
  • strains of the current invention are preferably also able to degrade protein under aerobic conditions in the presence of 2 mM bile.
  • strains selected from C. perfringens ATCC 13124; C. perfringens BB-081_Cpe; C. perfringens BB_031_Cpe; C. difficile DSM 1296; S. aureus subsp. aureus DSM 20231; S. gallinaceus DSM 15349; S. suis DSM 9682 and ⁇ . cecorum DSM 20683.
  • they are preferably characterized by a pathogen clearance of at least 10 mm, more preferably at least 13 mm, in a well diffusion antagonism assay on LBKelly agar plates with respect to C. perfringens type strain ATCC 13124, and/or by a pathogen clearance of at least 20 mm with respect to C. perfringens strains BB-08 l_Cpe and BB 03 l_Cpe, respectively.
  • the strains according to the invention are preferably further characterized by being able to grow in the presence of 0.05 wt.-% acetic acid, 0.05 wt.-% propionic acid and/or 0.2 wt.-% lactic acid.
  • the strains according to the invention are preferably further characterized by exhibiting at least one, preferably all, of the following enzymatic activities: cellulase activity; xylanase activity; catalase activity; superoxide dismutase activity.
  • they are preferably characterized by a protease activity of at least 10 mU/mL, more preferably at least 12 mU/mL, in particular at least 15 mU/mL, above all about 16 mU/mL, and by a xylanase activity of at least 300 mU/mL, more preferably at least 350 mU/mL, in particular at least 400 mU/mL, above all about 415 mU/mL.
  • the strains of the current invention preferably furthermore produce lactate and they are preferably further able to degrade mycotoxins.
  • the B. pumilus strains according to the invention are preferably further characterized by being able to grow in presence of 2 mM bile. In particular they are preferably characterized by being able to proliferate fast under such a high bile concentration.
  • the strains are preferably able to grow under high salt conditions, in particular in presence of 5 wt.-% of NaCl, more preferably in presence of 10 wt.-% of NaCl, for at least one day. Further the strains of the current invention preferably survive the high temperatures necessary for pelleting animal feed, in particular they preferably survive a temperature of 80°C, more preferably of 95° or 99°C, for at least 20 minutes.
  • Bacillus pumilus strains according to the current invention enhance animal health, in particular gut health, by a multifaceted mode of action, including the production of antibacterial metabolites with selective efficacy and the competition with pathogenic bacteria by better consuming the available nutrients, thereby suppressing effective establishment of pathogenic bacteria in the gut.
  • the enzymes produced by Bacillus pumilus may help to establish a balanced gut microbiota by providing predigested nutrients.
  • probiotics in comparison to antibiotics, that they do not attack bacteria indiscriminately nor do they lead to antibiotic resistant strains of pathogenic bacteria. Normally they are able to selectively compete with pathogenic bacteria by production of antimicrobial substances with specific efficacy, and are ideally able to simultaneously enhance the growth and viability of beneficial gut microflora. Further, they are preferably able to stimulate a systemic immune response in the treated animals.
  • the mutant strains of DSM 32539 of the current invention are preferably spontaneous mutants.
  • spontaneous mutant refers to mutants that arise from DSM 32539 without the intentional use of mutagens.
  • spontaneous mutants may be obtained by classical methods, such as growing the Bacillus pumilus strain in the presence of UV light, by applying high temperature or protoplast formation or in the presence of a certain antibiotic to which the parent strain is susceptible and testing any resistant mutants for improved biological activity or improved ability to enhance one or more of the indicia of animal health, in particular gut health. Other methods for identifying spontaneous mutants are known to those of ordinary skill in the art.
  • mutants of DSM 32539 are also comprised by the current invention.
  • One particular embodiment of the current invention are naturally non-occurring mutants, in particular spontaneous mutants as defined before, of the strain DSM 32539, characterized by the features as mentioned above.
  • the strains and preparations of the present invention are preferably administered orally to animals or human beings.
  • compositions such as feedstuffs, foodstuffs, drinking and rearing water as well as therapeutic compositions, containing a B. pumilus strain and/or a preparation of the current invention.
  • a further subj ect of the current invention is also the use of a B. pumilus strain and/or a preparation of the current invention as a probiotic ingredient (DFM) in feed or food products.
  • DFM probiotic ingredient
  • Preferred foodstuffs according to the invention are dairy products, in particular yoghurt, cheese, milk, butter and quark.
  • the cells of the strains of the current invention may be present, in particular in the compositions of the current invention, as spores (which are dormant), as vegetative cells (which are growing), as transition state cells (which are transitioning from growth phase to sporulation phase) or as a combination of at least two, in particular all of these types of cells.
  • the composition of the current invention comprises mainly or only spores.
  • the cells of the strains may also be used in non-living, inactivated form, as also the non-living cells are expected to still have a probiotic effect. Ways to inactivate the cells are known to those skilled in the art.
  • Bacillus pumilus strains of the current invention and compositions containing them when administered to animals, preferably enhance the health of such animals and/or improve the general physical condition of such animals and/or improve the feed conversion rate of such animals and/or decrease the mortality rate of such animals and/or increase the survival rates of such animals and/or improve the weight gain of such animals and/or increase the productivity of such animals and/or increase the disease resistance of such animals and/or increase the immune response of such animals and/or establish or maintain a healthy gut microflora in such animals and/or reduce the pathogen shedding through the feces of such animals.
  • the strains and compositions of the current invention might be used to assist in re-establishing a healthy balance of the gut microflora after administration of antibiotics for therapeutic purposes.
  • a further subject of the current invention is therefore a method of enhancing the health of animals and/or of improving the general physical condition of animals and/or of improving the feed conversion rate of animals and/or of decreasing the mortality rate of animals and/or of increasing the survival rates of animals and/or of improving the weight gain of animals and/or of increasing the productivity of animals and/or of increasing the disease resistance of animals and/or of increasing the immune response of animals and/or of establishing or maintaining a healthy gut microflora in animals and/or of reducing the pathogen shedding through the feces of animals, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to animals.
  • a further subject of the current invention is therefore also the use of strains and/or preparations and/or compositions of the current invention for enhancing the health of animals and/or for improving the general physical condition of animals and/or for improving the feed conversion rate of animals and/or for decreasing the mortality rate of animals and/or for increasing the survival rates of animals and/or for improving the weight gain of animals and/or for increasing the productivity of animals and/or for increasing the disease resistance of animals and/or for increasing the immune response of animals and/or for establishing or maintaining a healthy gut microflora in animals and/or for reducing the pathogen shedding through the feces of animals, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to animals.
  • a further subject of the current invention are therefore also the strains and preparations of the current invention as mentioned before and the compositions of the current invention, containing those strains, for enhancing the health of animals and/or for improving the general physical condition of animals and/or for improving the feed conversion rate of animals and/or for decreasing the mortality rate of animals and/or for increasing the survival rate of animals and/or for improving the weight gain of animals and/or for increasing the productivity of animals and/or for increasing the disease resistance of animals and/or for increasing the immune response of animals and/or for establishing or maintaining a healthy gut microflora in animals and/or for reducing the pathogen shedding through the feces of animals.
  • "Increasing the productivity of animals” refers in particular to any of the following: production of more or higher quality eggs, milk or meat or increased production of weaned offspring.
  • the methods and uses of the strains, preparations and compositions of the current invention can be therapeutic or non- therapeutic.
  • the methods and uses are non-pharmaceutic, in particular feeding applications.
  • a further subject of the current invention is a method of controlling and/or avoiding detrimental environmental effects of manure or contaminated liquids, the method comprising the step of applying to manure, contaminated liquids, litter, a pit, or a manure pond at least one strain, one preparation and/or one composition according to the current invention.
  • composition is applied in liquid form, for example by spraying, or as a powder, for example by strewing.
  • a further subject of the current invention is a method of controlling and/or improving the consistency of litter, in particular a method of ensuring a solid consistency of litter and/or a method of avoiding foot pad lesions, the method comprising the step of feeding animals, in particular poultry, with at least one strain, one preparation and/or one composition according to the current invention.
  • strains and preparations according to the invention can also be used for improving the quality of water.
  • a further subject of the current invention is therefore also a method of controlling and/or improving the quality of water or aqueous solutions, in particular of drinking water and/or rearing water, comprising the step of applying to water or an aqueous solution at least one strain and/or at least one preparation and/or at least one composition of the current invention.
  • strains and preparations according to the invention can also be used for treating microbial diseases of plants.
  • a further subject of the current invention is therefore also a method of treating and/or preventing microbial diseases of plants, in particular of cultivated plants, comprising the step of applying to the plants at least one strain and/or at least one preparation and/or at least one composition of the current invention.
  • the application may be carried out in liquid form, such as by spraying, or in solid form, in particular as a powder, preferably as a formulated powder.
  • the strains, preparations and compositions of the current invention preferably an improvement of at least one of the features as mentioned before is realized, wherein realization of the feature preferably means an improvement of at least 1 %, more preferably of at least 3 or at least 5 %, in comparison to an adequate negative control.
  • realization of the feature preferably means an improvement of at least 1 %, more preferably of at least 3 or at least 5 %, in comparison to an adequate negative control.
  • negative control averages known in the animal husbandry field may be used, but preferably as negative control animals which are subjected to the same treatment like the animals tested are used, but without administration of the strains and/or preparations of the current invention.
  • the strains, preparations and compositions of the current invention may be administered or fed to an animal in an amount effective to inhibit and/or decrease the growth of pathogenic bacteria in the animal gut.
  • Such pathogenic bacteria include Clostridia, Listeria, Salmonella, Enterococci, Staphylococci, Aeromonas, Streptococci, Campylobacter, Escherichia coli, Shigella, Haemophilus, Brachyspira and Vibrio.
  • the methods of the present invention may be used to decrease the amount of pathogenic bacteria, viruses and protozoans shed in animal feces.
  • the methods of the present invention may also be used to maintain or increase the growth of beneficial bacteria, such as lactic acid bacteria, in the animal gut. By decreasing pathogenic bacteria and/or increasing or maintaining beneficial bacteria, the compositions of the present invention are able to maintain an overall healthy gut microflora.
  • a further subject of the current invention are also the strains, preparations and compositions of the current invention for inhibiting and/or decreasing the growth of pathogenic bacteria and/or for maintaining and/or increasing the growth of beneficial bacteria in an animal gut, wherein the pathogenic bacteria are preferably selected from Clostridia, in particular from C. perfringens, C. difficile, C. novyi, C. septicum and C. colinum, from Listeria, in particular from L. monocytogenes, L. seeligeri and L. welshimeri, from Salmonella, in particular S. enterica including the subspecies enterica, arizonae, bongori and in particular the serovars, S. gallinarum, S. pullorum, S.
  • the pathogenic bacteria are preferably selected from Clostridia, in particular from C. perfringens, C. difficile, C. novyi, C. septicum and C. colinum, from Listeria, in particular from L. monocytogenes, L
  • S. enteritidis S. cholerasuis, S. heidelberg and S. infantis
  • Enterococci in particular E. faecalis, E. faecium and E. cecorum
  • Staphylococci in particular S. aureus
  • Aeromonas from Streptococci, in particular S. suis and S. gallinaceus
  • Campylobacter in particular C. jejuni and C. coli
  • Escherichia coli from Haemophilus, in particular Haemophilus parasuis, from Brachyspira, in particular
  • Brachyspira hyodysenteriae and from Vibrio, in particular V. parahemolyticus and V. harveyi, and the beneficial bacteria are preferably selected from lactic acid bacteria, in particular from lactobacilli and bifidobacteria.
  • the amount of at least one pathogenic bacterium, in particular the amount of C. perfringens is reduced by at least 0.5 log, more preferably by at least 1 log, 2 log, or 3 log.
  • a further subject of the current invention are also the strains, preparations and compositions of the current invention for inhibiting and/or decreasing the growth of pathogenic bacteria and/or for maintaining and/or increasing the growth of beneficial bacteria in an animal gut, wherein the pathogenic bacteria are preferably selected from Clostridia, in particular from C. perfringens, C. difficile, C. novyi, C. septicum and C. colinum, from Listeria, in particular from L. monocytogenes, L. seeligeri and L.
  • Brachyspira hyodysenteriae and from Vibrio, in particular V. parahemolyticus and V. harveyi, and the beneficial bacteria are preferably selected from lactic acid bacteria, in particular from lactobacilli and bifidobacteria.
  • the occurrence and/or increased growth of the pathogenic bacteria does or can lead to the outbreak of certain diseases.
  • Clostridium perfringens can lead to the outbreak of gut diseases, in particular to the outbreak of necrotic enteritis in swine and poultry.
  • the occurrence and/or increased growth of C. perfringens can also lead to the outbreak of further diseases like bacterial enteritis, gangrenous dermatitis and colangiohepatitis.
  • Even the mildest form of infection by C. perfringens can already be accompanied by diarrhea, which results in wet litter and by that may lead to secondary diseases like foot pad dermatitis. While C.
  • perfringens type C generally is considered to be the primary cause of necrotic enteritis and necrohemorrhagic enteritis in piglets, type A has been linked to enteric disease in suckling and feeding pigs with mild necrotic enterocolitis and villous atrophy.
  • Clostridium difficile is an important emerging pathogen that causes diarrhea primarily in neonatal swine. Affected piglets may have dyspnea, abdominal distention, and scrotal edema. Staphylococcus aureus subsp. aureus can cause bumblefoot in chickens, streptococcal mastitis in sows and it is capable of generating toxins that produce food poisoning in the human body.
  • E. cecorum is known to cause lameness, arthritis and osteomyelitis in broilers usually caused by an inflammation of a joint and/or bone tissue. Further E. cecorum can cause an inflammation of the pericardium.
  • S. gallinaceus can cause septicaemia in poultry.
  • S. suis is an important pathogen in pigs and one of the most important causes of bacterial mortality in piglets after weaning causing septicemia, meningitis and many other infections. Pathogens can cause further diseases like polyarthritis, fibrinous polyserositis, post-weaning enteric disorders like post-weaning diarrhea and edema disease and swine dysentery.
  • a further subject of the current invention is therefore also a therapeutic composition comprising the strains and/or compositions of the current invention as mentioned before.
  • a preferred subject in this context is therefore a therapeutic composition for treatment and/or prevention of necrotic enteritis and necrohemorrhagic enteritis, in particular sub-clinical necrotic enteritis and necrohemorrhagic enteritis, in animals, preferably poultry or swine, comprising the strains and/or compositions of the current invention as mentioned before.
  • Another preferred subject in this context is therefore a therapeutic composition for treatment and/or prevention of bacterial enteritis, gangrenous dermatitis, colangiohepatitis, clostridiosis, diarrhea, dyspnea, abdominal distention, scrotal edema, bumblefoot, foot pad dermatitis, streptococcal mastitis, lameness, arthritis, polyarthritis, fibrinous polyserositis, post-weaning enteric disorders like post- weaning diarrhea and edema disease, dysentery, osteomyelitis, inflammation of joints and/or bone tissue, inflammation of the pericardium, splenomegaly, hepatomegaly, renomegaly, congestion, necrosis, infarction in the liver or spleen, valvular endocarditis, septicemia and/or meningitis, in animals, preferably in poultry or swine, comprising the strains and/or compositions of the current invention as mentioned before
  • a further subject of the current invention is therefore also the treatment and/or prevention of a disease, in particular of a gut disease, preferably of necrotic enteritis or necrohemorrhagic enteritis, in particular of sub-clinical necrotic enteritis or sub-clinical necrohemorrhagic enteritis, in poultry or swine, wherein a strain and/or composition and/or preparation of the current invention is administered to an animal in need thereof.
  • a further subject of the current invention is therefore also the treatment and/or prevention of a disease, preferably a disease of poultry or swine, selected from bacterial enteritis, gangrenous dermatitis, colangiohepatitis, clostridiosis, diarrhea, dyspnea, abdominal distention, scrotal edema, bumblefoot, foot pad dermatitis, streptococcal mastitis, lameness, arthritis, polyarthritis, fibrinous polyserositis, post- weaning enteric disorders like post-weaning diarrhea and edema disease, dysentery, osteomyelitis, inflammation of joints and/or bone tissue, inflammation of the pericardium, splenomegaly, hepatomegaly, renomegaly, congestion, necrosis, infarction in the liver or spleen, valvular endocarditis, septicemia and/or meningitis, wherein a strain and/or composition and/or preparation
  • strains and/or preparations and/or compositions of the current invention can be administered to animals in feed and/or drinking water over multiple days throughout the animal's life or during particular stages or portions of the animal's life.
  • the strains and/or compositions can be administered only in a starter diet or only in a finisher diet of farm animals.
  • a particular subject of the current invention is also a method of enhancing the health of human beings and/or of improving the general physical condition of human beings and/or of increasing the disease resistance of human beings and/or of increasing the immune response of human beings and/or of establishing or maintaining a healthy gut microflora in human beings, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to human beings.
  • a further subject of the current invention is therefore also the use of strains and/or preparations and/or compositions of the current invention for enhancing the health of human beings and/or for improving the general physical condition of human beings and/or for increasing the disease resistance of human beings and/or for increasing the immune response of human beings and/or for establishing or maintaining a healthy gut microflora in human beings, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to human beings.
  • compositions of the present invention in particular the feed, food and pharmaceutical compositions as well as the drinking or rearing water, preferably comprise the strains of the current invention and are administered to animals at a rate of about lxlO 3 to about 2x10 12 CFU/g feed or ml water, in particular in a rate of about lxlO 3 or about lxlO 4 or about lxlO 5 or about lxlO 6 or about lxlO 7 or about lxlO 8 or about lxlO 9 or about lxlO 10 or about lxlO 11 or about lxlO 12 CFU/g feed or ml water, preferably in an amount of about lxlO 4 to about lxlO 10 CFU/g feed or ml water, more preferably in an amount of lxl 0 4 to lxlO 7 CFU/g feed or ml water.
  • preferred amounts of the strains and/or preparations of the current invention in the feed, food and water compositions of the current invention range preferably from 0.1 wt.-% to 10 w - %, more preferably from 0.2 wt.-% to 5 wt.-%, in particular from 0.3 wt.-% to 3 wt.-%.
  • the methods of the present invention may be used for all kind of animals, in particular all kind of non- human and non-insect animals, more preferably all kind of vertebrates such as mammals, aquatic animals and birds.
  • Animals that may benefit from the current invention include but are not limited to farm animals, pets, exotic animals, zoo animals, aquatic animals, animals used for sports, recreation or work.
  • Pets are preferably selected from dogs, cats, domestic birds and domestic exotic animals.
  • Aquatic animals are preferably selected from finfish and crustaceans which are preferably intended for human nutrition. These include, in particular, carp, tilapia, catfish, tuna, salmon, trout, barramundi, bream, perch, cod, shrimps, lobster, crabs, prawns and crayfish.
  • Preferred types of salmon in this context are the Atlantic salmon, red salmon, masu salmon, king salmon, keta salmon, coho salmon, Danube salmon, Pacific salmon and pink salmon.
  • Further preferred aquatic animals are fanning fish which are subsequently processed to give fish meal or fish oil.
  • the fish are preferably herring, pollack, menhaden, anchovies, capelin or cod.
  • the animals are farm animals, which are raised for consumption or as food-producers, such as poultry, swine and ruminants.
  • the poultry may be selected from productive or domestic poultry, but also from fancy poultry or wild fowl.
  • Preferred productive poultry in this context are chickens, turkeys, ducks and geese.
  • the productive livestock in this context is preferably poultry optimized for producing young stock or poultry optimized for bearing meat.
  • Preferred fancy poultry or wild fowl are peacocks, pheasants, partridges, chukkars, guinea fowl, quails, capercaillies, grouse, pigeons and swans, with quails being especially preferred.
  • Ruminants according to the current invention are preferably selected from cattle, goat and sheep.
  • the compositions of this invention may be fed to preruminants to enhance their health and, in particular, to decrease the incidence of diarrhea in these animals.
  • Preruminants are ruminants, including calves, ranging in age from birth to about twelve weeks.
  • the compositions of the current invention may comprise at least one carrier or typical feed ingredients or combinations thereof.
  • Suitable carriers are inert formulation ingredients added to improve recovery, efficacy, or physical properties and/or to aid in packaging and administration. Such carriers may be added individually or in combination. These carriers may be selected from anti-caking agents, anti-oxidation agents, bulking agents, and/or protectants.
  • useful carriers include polysaccharides (in particular starches, maltodextrins, methylcelluloses, gums, chitosan and/or inulins), protein sources (in particular skim-milk powder and/or sweet- whey powder), peptides, sugars (in particular lactose, trehalose, sucrose and/or dextrose), lipids (in particular lecithin, vegetable oils and/or mineral oils), salts (in particular sodium chloride, sodium carbonate, calcium carbonate, chalk, limestone, magnesium carbonate, sodium phosphate, calcium phosphate, magnesium phosphate and/or sodium citrate), and silicates (in particular clays, in particular beolite clay, amorphous silica, fumed/precipitated silicas, zeolites, Fuller's earth, baylith, clintpolite, montmorillonite, diatomaceous earth, talc, bentonites, and/or silicate salts like aluminium, magnesium and/or calcium silicate
  • Suitable carriers for animal feed additives are set forth in the American Feed Control Officials, Inc.' s Official Publication, which publishes annually. See, for example Official Publication of American Feed Control Officials, Sharon Krebs, editor, 2006 edition, ISBN 1-878341-18-9.
  • the carriers can be added after concentrating the fermentation broth and/or during and/or after drying.
  • Preferred carriers according to the invention are selected from calcium carbonate, diatomaceous earth and vegetable oil.
  • a preferred embodiment of the current invention are concentrate compositions, in particular feed additive compositions, i.e. compositions suitable for preparing a feed composition, which comprise at least one strain of the current invention and at least one carrier as mentioned before, wherein the at least one strain is preferably comprised in an amount of 0.1 to 10 wt.-%, more preferably in an amount of 0.2 to 5 wt.-%, in particular in an amount of 0.3 to 3 wt.-%, above all in an amount of 0.4 to 2.2 wt.-%, and the at least one carrier is preferably comprised in an amount of at least 90 wt.-%, preferably in an amount of 90 to 99.9 wt.-%, more preferably in an amount of 95 to 99.8 wt.-%, in particular in an amount of 97 to 99.7 wt.-%, above all in an amount of 97.8 to 99.6 wt.-%, and wherein the carrier consists preferably substantially of limestone, in particular of limestone with
  • compositions of the current invention which contain stabilized strains, can be used for the preparation of feed and pharmaceutical compositions as well as drinking and rearing water which preferably comprise the strains according to the invention in an amount as mentioned in the specification above.
  • 50 to 1000 grams of such a concentrate composition in particular 50, 100, 250, 500 or 1000 grams of such a concentrate composition, are used per ton of feed, drinking or rearing water to provide compositions which can be used for feeding animals.
  • These concentrate compositions preferably comprise at least one strain of the current invention in an amount of lxlO 9 to 2xlO u CFU, in particular 2xl0 9 to lxlO 11 CFU, per g of the concentrate composition.
  • feed and food compositions can be prepared by mixing the concentrate compositions with typical feed or food ingredients, respectively.
  • Suitable typical animal feed ingredients which may be contained in the compositions according to the invention and/or used in the preparation of feed compositions starting from concentrate compositions according to the invention include one or more of the following: proteins, carbohydrates, fats, further probiotics, prebiotics, enzymes, vitamins, immune modulators, milk replacers, minerals, amino acids, coccidiostats, acid-based products and/or medicines, such as antibiotics.
  • Carbohydrates containing components which may be used according to the invention are for example forage, roughage, wheat meal, sunflower meal or soya meal, and mixtures thereof.
  • Proteins containing components which may be used according to the invention are for example soya protein, pea protein, wheat gluten or corn gluten, and mixtures thereof.
  • Fats containing components which may be used according to the invention are in particular oils, of both animal and plant origin, like vegetable oils, for example soya bean oil, rapeseed oil, sunflower seed oil, flaxseed oil or palm oil, fish oil, and mixtures thereof.
  • Proteins containing components which additionally contain fats are for example fish meal, krill meal, bivalve meal, squid meal or shrimp shells, as well as combinations thereof.
  • Further probiotics (DFM) which may be used according to the invention in combination with the strains and preparations of the invention are preferably bacteria selected from the species Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus pumilus, Bacillus laterosporus, Bacillus coagulans, Bacillus alevi, Bacillus cereus, Bacillus badius, Bacillus thurigiensis, Enterococcus faecium, and Pediococcus acidilactici.
  • Bacillus subtilis DSM 32540 (as deposited with the DSMZ on June 14, 2017 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure) and derivatives thereof, Bacillus licheniformis DSM 32314 and Bacillus subtilis DSM 32315 (both deposited with the DSMZ on May 12, 2016 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure) and derivatives thereof, Bacillus subtilis PB6 (as described in US Patent No. 7,247,299 and deposited as ATCC Accession No.
  • PTA-6737 which is sold by Kemin under the trademark CLOSTAT®, Bacillus subtilis C-3102 (as described in US Patent No. 4,919,936 and deposited as FERM BP- 1096 with the Fermentation Research Institute, Agency of Industrial Science and Technology, in Japan), sold by Calpis as CALSPORTN®, Bacillus subtilis DSM 17299, as sold by Chr. Hansen under the trademark GalliPro®, Bacillus licheniformis DSM 17236, as sold by Chr. Hansen under the trademark GalliProTect®, a mixture of Bacillus licheniformis DSMZ 5749 and Bacillus subtilis DSMZ 5750 spores, as sold by Chr. Hansen under the trademark
  • Other non-Bacillus probiotics such as Saccharomyces cerevisiae, Pichia pastoris, Aspergillus niger, Aspergillus oryzae, or Hansenula, may also be used in compositions of the present invention.
  • compositions of the present invention further probiotics which are known to be useful to the human health may be used such as lactic acid producing bacteria, in particular lactobacilli, or Bifidobacteria. If said further probiotics are not formulated as part of the compositions of the present invention, they may be administered together (either at the same time or at different times) with the compositions of the present invention.
  • Prebiotics which may be used according to the invention are preferably oligosaccharides, in particular selected from galactooligosaccharides, silayloligosaccharides, lactulose, lactosucrose,
  • fructooligosaccharides palatinose or isomaltose oligosaccharides, glycosyl sucrose,
  • maltooligosaccharides isomaltooligosaccharides, cyclodextrins, gentiooligosaccharides, soybean oligosaccharides, xylooligosaccharides, dextrans, pectins, polygalacturonan, rhamnogalacturonan, mannan, hemicellulose, arabinogalactan, arabinan, arabinoxylan, resistant starch, mehbiose, chitosan, agarose, inulin, tagatose, polydextrose, and alginate.
  • Enzymes which may be used in feed compositions according to the invention and which may aid in the digestion of feed are preferably selected from phytases (EC 3.1 .3.8 or 3.1.3.26), xylanases (EC 3.2.1.8), galactanases (EC 3.2.1 .89), galactosidases, in particular alpha-galactosidases (EC 3.2.1.22), proteases (EC 3.4), phospholipases, in particular phospholipases Al (EC 3.1 .1.32), A2 (EC 3.1.1.4), C (EC 3.1.4.3), and D (EC 3.1.4.4), lysophospholipases (EC 3.1 .1.5), amylases, in particular alpha- amylases (EC 3.2.1.1 ); lysozymes (EC 3.2.1 .17), glucanases, in particular beta-glucanases (EC 3.2.1.4 or EC 3.2.1.6), glucoamylases, cellulases, pec
  • phytases examples include Bio-FeedTM Phytase (Novozymes), Ronozyme® P and HiPhosTM (DSM Nutritional Products), NatuphosTM (BASF), Finase® and Quantum® Blue (AB Enzymes), the Phyzyme® XP (Verenium/DuPont) and Axtra® PHY (DuPont).
  • Other preferred phytases include those described in e.g. WO 98/28408, WO 00/43503, and WO 03/066847.
  • xylanases examples include Ronozyme® WX and G2 (DSM Nutritional Products), Econase® XT and Barley (AB Vista), Xylathin® (Verenium) and Axtra® XB
  • proteases (Xylanase/beta-glucanase, DuPont).
  • examples of commercially available proteases include Ronozyme® Pro Act (DSM Nutritional Products).
  • Vitamins which may be used according to the invention are for example vitamin A, vitamin D3, vitamin E, vitamin K, e.g., vitamin K3, vitamin B 12, biotin, choline, vitamin B 1 , vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. , Ca-D-panthothenate, or combinations thereof.
  • Immmune modulators which may be used are for example antibodies, cytokines, spray-dried plasma, interleukins, or interferons, or combinations thereof.
  • Minerals which may be used according to the invention are for example boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, zinc, calcium, magnesium, potassium, or sodium, or combinations thereof.
  • Amino acids which may be used according to the invention are for example lysine, alanine, threonine, methionine or tryptophan, or combinations thereof.
  • a further embodiment of the current invention is a method of preparing an animal feed composition
  • This method may comprise for example also a pelleting step.
  • Standard pelleting processes known to those of skill in the art may be used, including extrusion processing of dry or semi-moist feeds.
  • Preferred pelleting temperatures are between about 65° C and about 120° C.
  • the strains and compositions of the present invention can be obtained by culturing the strains of the current invention according to methods well known in the art, including by using the media and other methods as described for example in US 6,060,051, EP0287699 or US2014/0010792.
  • Conventional large-scale microbial culture processes include submerged fermentation, solid state fermentation, or liquid surface culture. Towards the end of fermentation, as nutrients are depleted, the cells of the strains begin the transition from growth phase to sporulation phase, such that the final product of fermentation is largely spores, metabolites and residual fermentation medium. Sporulation is part of the natural life cycle of these strains and is generally initiated by the cell in response to nutrient limitation.
  • Fermentation is configured to obtain high levels of colony forming units of the Bacillus pumilus cells and to promote sporulation.
  • the bacterial cells, spores and metabolites in culture media resulting from fermentation may be used directly or concentrated by conventional industrial methods, such as centrifugation, tangential-flow filtration, depth filtration, and evaporation.
  • the concentrated fermentation broth may be washed, for example via a diafiltration process, to remove residual fermentation broth and metabolites.
  • the fermentation broth or broth concentrate can be dried with or without the addition of carriers using conventional drying processes or methods such as spray drying, freeze drying, tray drying, fluidized-bed drying, drum drying, or evaporation.
  • the resulting dry products may be further processed, such as by milling or granulation, to achieve a specific particle size or physical format.
  • Carriers, as described above, may also be added post-drying.
  • Preparations of the strains of the current invention may be cell-free preparations or preparations containing cell debris or preparations containing a mixture of intact cells and cell debris.
  • Cell-free preparations of the strains of the current invention can be obtained for example by centrifugation and/or filtration of fermentation broth. Depending on the technique used, these cell-free preparations may not be completely devoid of cells, but may still comprise a smaller amount of cells.
  • the supernatant of the cells comprises a mixture of such compounds, in particular metabolites, enzymes and/or peptides, as secreted by the cells.
  • the preparation of the strains is a supernatant of the fermentation broth.
  • compositions comprising cell debris of the strains may be obtained by rupturing the cells applying techniques as known to those of skill in the art, for example by mechanical means or by applying high pressure. Depending on the degree of force applied, a composition comprising only ruptured cells or a composition comprising a mixture of cell debris and intact cells is obtained. Homogenization of the cells may be realized for example by utilizing a French cell press, sonicator, homogenizer,
  • Cell-free preparations of the current invention comprise also preparations which are obtained by first rupturing the cells by applying techniques as mentioned before and subsequently removing the cell debris and the remaining intact cells. Removing of the cell debris and remaining intact cells can be carried out in particular by centrifugation and/or filtration.
  • the preparations of the strains of the current invention may comprise as active compounds at least one metabolite, preferably a mixture of metabolites, as further described below, and/or at least one enzyme selected from proteases, in particular subtilisin, xylanases and/or cellulases, and/or at least one peptide, and/or combinations thereof.
  • a preparation containing an effective mixture of metabolites as contained in the strains of the current invention and/or as contained in the cell preparations as mentioned before, can be obtained for example according to the methods set forth in US Patent No. 6,060,051.
  • the preparation can be obtained by precipitating the metabolites as contained in the preparations mentioned before by using organic solvents like ethyl acetate and subsequent redissolving of the precipitated metabolites in an appropriate solvent.
  • the metabolites may subsequently be purified by size exclusion filtration that groups metabolites into different fractions based on molecular weight cut-off.
  • the preparation containing an effective mixture of metabolites of the current invention preferably comprises at least five, more preferably at least 6, 7, 8, 9, 10 or 12, in particular all metabolites of the strains of the invention.
  • the content of metabolites of the strain DSM 32539 is depicted in Table 5.1.
  • the metabolites possess preferably a molecular weight of between 200 and 1200 Dalton, more preferably of between 300 and 1100 Dalton.
  • an effective amount of the strains and/or preparations and/or compositions of the current invention is used in the embodiments of the current invention.
  • an effective amount refers to an amount which effects at least one beneficial effect to an animal and/or to the environment, in particular with respect to the features as already mentioned before, in comparison to an animal that has not been administered the strains and/or preparations and/or compositions of the current invention, but besides that has been administered the same diet (including feed and other compounds).
  • a therapeutic amount of the strains and/or preparations and/or compositions of the current invention is used.
  • the term "therapeutic amount” refers to an amount sufficient to ameliorate, reverse or prevent a disease state in an animal.
  • Optimal dosage levels for various animals can easily be determined by those skilled in the art, by evaluating, among other things, the composition's ability to (i) inhibit or reduce pathogenic bacteria in the gut at various doses, (ii) increase or maintain levels of beneficial bacteria and /or (iii) enhance animal health, in particular gut health, at various doses.
  • Example 1 Strain characteristics relevant to survival in the gastrointestinal tract.
  • Bacillus pumilus strains were screened from various environmental samples in order to obtain a superior strain as animal direct-fed microbial / probiotic. As the strain is intended to reach its full potential in the intestine of the target animal, the strain was pre-screened to withstand various environmental and gut related conditions. Strain spores were generated (Nicholson and Setlow 1990), washed and incubated at 80 °C for 20 minutes (pasteurization), then titrated in logarithmic / 1 in 10 dilutions using veal infusion broth agar (VI, DifcoTM, no. 234420, Becton Dickinson GmbH, Heidelberg, Germany).
  • the second highest dilution prior to no growth was stored at -80 °C and used as standardized starting point for all further assessments from spore state.
  • survival of acid exposure was assessed based on Larsen et al. (2014).
  • Growth of vegetative cells was furthermore assessed at low pH indicating growth under stomach/proventriculus and gizzard conditions, as well as in presence of up to 2 mM bile (B8631, CAS 8008-63-8, Sigma-Aldrich) at pH 7 in order to confirm strain growth at the proximal part of the small intestine right after clearance of the stomach or gizzard (Argenzio 2004b; Trampel and Duke 2004).
  • strain fitness in the anaerobe intestine was assessed by inoculating standardized spore solutions under anaerobic conditions (AnaeroPakTM, Thermo Fisher Scientific) in VI medium supplemented with 2.5 mM KNO3 (Glaser et al. 1995). Furthermore was the anaerobe proteolytic and cellulytic activity of strains assessed on VI agar plates supplemented with 1% skim milk powder (70166, Sigma-Aldrich) or 0.1% water insoluble AZCL-HE cellulose (I-AZCEL, Megazyme International, Bray, Ireland).
  • Osmotic stress as also found in the gut (Argenzio 2004b; Trampel and Duke 2004), was assessed by determining growth on VI agar with addition of 10 wt.-% NaCl (den Besten et al. 2009). Finally, spore heat stability was assessed to determine pelleting stability by exposing spores to 99 °C for 20 min (Palop et al. 1996) and subsequent inoculation on VI agar.
  • Bacillus pumilus strain DSM 32539 survived simulated gastric passage, growth of the strain was observed starting at pH 6. Strain DSM 32539 grew anaerobically and was able to degrade water- insoluble cellulose and protein under anaerobic conditions. Further, it was able to degrade protein under aerobic conditions in the presence of 2mM bile. Strain DSM 32539 was able to grow in presence of 2 mM bile, in presence of 0.3 wt.-% porcine bile and in presence of 0.3 wt.-% chicken bile as well as in presence of 10 wt.-% NaCl. Strain DSM 32539 reached an average spore count of 10.4 x 10 s CFU/mL, and spores of strain DSM 32539 were viable after exposure to 99°C for 20 min.
  • Reece, W. O. (ed.) Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 25; Georgia University Press, Ithaca, New York, USA.
  • AUC5 area under the curve between time point 0 and 5 h in optical density x h
  • AUC10 area under the curve between time point 0 and 10 h in optical density x h
  • Tmax time in h until maximum optical density was reached.
  • strain DSM 32539 reached its maximum OD in presence of 0.3 wt.-% porcine bile 11.25 h faster than the benchmark Bacillus licheniformis strain DSM 17236.
  • strain DSM 32539 grew 1.5 times faster during the first 30 h, compared to growth of benchmark strain DSM 17236.
  • DSM 32539 is able to growth in the presence of 0.3 % chicken bile.
  • VI medium was adjusted to pH 6 using Mcllvaine buffer (Palop et al. 1996) and subsequently supplemented with 0,05 % acetic acid (HA, 537020, CAS 64-19-7, Sigma-Aldrich), 0,05 % propionic acid (HP, P1386, CAS 79-09-4, Sigma-Aldrich) or 0,2 % lactic acid (HL, W261106, CAS 50-21-5, Sigma-Aldrich). Results can be found in Table 3.1.
  • Example 4 Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - quantitative assessment of enzymatic activity.
  • DFM direct-fed microbial
  • strains DSM 32539, DSM 17236 and DSM 17299 were compared evaluating the respective aerobe xylanolytic and proteolytic activity.
  • Xylanase activity were determined as described in Larsen et al. (2014).
  • starter and main culture of strains were grown in VIB at 37°C as previously described.
  • strain DSM 32539 demonstrated significant 52.5 fold increased xylanase activity comparing to benchmark strain DSM 17236 and 1.7 fold increased protease activity comparing to benchmark strain DSM 17299.
  • Example 5 Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - expression of metabolites and pathogen inhibition.
  • DFM direct-fed microbial
  • strains DSM 32539 and benchmark strain DSM 17299 were compared evaluating the respective number of metabolites expressed and pathogens inhibited in the respective media.
  • starter cultures were grown and tests performed as described in Scholz et al. (2011). From 10 mL Luria Bertami broth (LB, Thermo Fisher Scientific) culture grown for 24 h at 37°C and 160 rpm in 100 mL flask, 100 uL were transferred to main culture. Main culture was grown either in 10 mL LB containing 0.2 mL / L KellyT trace metal solution
  • a well diffusion antagonisms test with 6 different pathogens Clostridium perfringens, Clostridium difficile DSM 1296, Enterococcus cecorum DSM 20683, Staphylococcus aureus subsp. aureus DSM 20231, Streptococcus gallinaceus DSM 15349 and Streptococcus suis ATCC 43765 was performed.
  • Three pathogenic C. perfringens candidates were tested being C. perfringens type strain ATCC 13124 from Teo and Tan (2005), as well as two pathogenic C. perfringens field isolates from swine, obtained from RIP AC-LABOR GmbH, Potsdam-Golm, Germany. The C.
  • Strains BB-08 l_Cpe and BB-03 l_Cpe were isolated from necrotic enteritis positive swine digestive tract. Strain BB-08 l_Cpe is cpb2 positive (Songer et al. 2005) and netB negative and Strain BB-03 l_Cpe tested positive for ⁇ 2 -toxin (Allaart et al. 2012). Strain ATCC 13124 is known to be alpha-toxigenic Type A strain serving as a type strain for Clostridia.
  • Clostridium difficile is an important emerging pathogen that causes diarrhea primarily in neonatal swine (Songer et al. 200). Affected piglets may have dyspnea, abdominal distention, and scrotal edema.
  • Diarrhea may not be present in all pigs affected.
  • DSM 1296 is a known type strain for C. difficile and produces cytotoxin.
  • Staphylococcus aureus subsp. aureus can cause bumblefoot in chickens (McMullin 2004), streptococcal mastitis in sows (Contreras et al. 2011) and it is capable of generating toxins that produce food poisoning in the human body (2016 Centers for Disease Control and Prevention).
  • DSM 20231 is a serotype 3 type strain.
  • E. cecorum is known to cause lameness, arthritis and osteomyelitis in broilers usually caused by an inflammation of a joint and/or bone tissue. Additional E. cecorum can cause an inflammation of the pericardium [Kense et al. 2011].
  • DSM 20683 was isolated from caecum of a chicken.
  • S. gallinaceus can cause septicaemia in poultry.
  • the gross lesions included splenomegaly, hepatomegaly, renomegaly and congestion. Multiple areas of necrosis and/ or infarction in the liver and spleen associated with valvular endocarditis were also observed [Collins et al. 2002].
  • ATCC 43765 belongs to Serological group: R; serovar 2 and was isolated from pigs. Bacillus strains were grown in 10 mL TSBYE (30 g/1 TSB + 6 g/1 Yeast extract) or LB-Kelly (LB-
  • Table 5.2 Comparison of Bacillus pumilus DSM 32539 , DSM 17236 and DSM 17299 inhibitory capacity on pathogenic Clostridium strains in well diffusion antagonism assays on LB Kelly medium, values in mm clearance of pathogen.
  • DSM 32539 is able to inhibit the growth of S. aureus subsp. aureus, S. gallinaceus and S. suis very effectively, in particular in comparison to DSM 17299.
  • Table 5.4 Comparison of Bacillus pumilus DSM 32539, DSM 17236 and DSM 17299 inhibitory capacity on pathogenic Enterococcus cecorum in well diffusion antagonism assays on TSBYE medium, values in mm clearance of pathogen.
  • the strain was grown in LB medium supplemented with glucose for 15 hrs at 37° C and 200 rpm in shaking flasks.
  • the cultures were adjusted to an optical density ⁇ of 1.0 and 10 ⁇ of the cultures were spotted onto TSBYE (30 g/1 TSB + 6 g/1 Yeast extract) or LB-Kelly (LB-Media supplemented with trace elements solution of DSMZ media 1032) agar plates, which were incubated at 37° C under aerobic conditions and at 37° C under 0.2 % oxygen for 15 hrs.
  • Bacillus pumilus strain DSM 32539 displayed catalase activity when grown under aerobic conditions.
  • Table 6.2 Assessment of catalase activity of colonies of Bacillus pumilus strain DSM 32539 grown as biofilm on LB-Kelly or TSBYE medium under 0.2 % oxygen.
  • Bacillus pumilus strain DSM 32539 displayed catalase activity also when grown under 0.2% oxygen.
  • Catalase activity was analyzed in protein extracts obtained from planktonic cells grown under aerobic conditions as well.
  • the strain DSM 32539 was grown for 15 hrs in LB medium containing glucose at 37° C and 200 rpm in shaking flasks. 8 ml of the cell cultures were harvested by centrifugation for 10 min at 4° C and 3000 rpm and the pellet was resuspended in PBS pH 7,3. Soluble cell extracts were obtained by using a ribolyser. The disrupted cells were centrifuged for 10 min at 4° C and 13000 rpm and the supernatant was used for further steps. The protein concentration of the protein extracts was determined by the method of Bradford with bovine serum albumin as a standard (Bradford, 1976).
  • the concentration of the protein extracts was adjusted with PBS pH 7,3, the protein extracts were mixed with native sample loading buffer (2x, VWR) and native gel electrophoresis (10 % non- denaturing polyacrylamide gels, Biorad) was applied to separate the proteins at 4° C.
  • Catalase activity in cell extracts from planktonic cells was then detected by staining the gel in a staining solution of 1 % FeCb and 1 % K.3Fe(CN)6 (Woodbury et al., 1971). Catalase activity can be seen as bright bands.
  • Bacillus pumilus strain DSM 32539 displayed catalase activity also under these specific conditions as tested.
  • Superoxide dismutase activity was analyzed in protein extracts from cells grown under aerobic conditions as well. Cell extracts were obtained by the method described above and proteins were separated by performing native gel electrophoresis at 4° C. Superoxide dismutase activity was detected by staining the gel with a nitroblue tetrazolium staining method adapted from Beauchamp and Fridovich (1971).
  • Bacillus pumilus strain DSM 32539 displayed superoxide dismutase activity under the conditions tested. References Aluwong, T.; Kawu, M.; Raji, M.; Dzenda, T.; Govwang, F.; Sinkalu, V. and Ayo, J. (2013). Effect of Yeast Probiotic on Growth, Antioxidant Enzyme Activities and Malondialdehyde Concentration of Broiler Chickens. Antioxidants 2: 326-339.
  • Lactate production was determined as follows: Precultures of the strains were grown over night at 37 °C in 10 mL TSBYE (30 g/1 TSB + 6 g/1 Yeast extract) under aerobic conditions. Main culture was inoculated with an ⁇ of 0.2 in 10 ml TSBYE complemented with 25 g/1 sucrose and 5 mM KNO3 in 15 ml Falcon Tubes at 37 °C without shaking for 48 h. Lactate was measured in the supernatant with HPLC-UV.
  • Strain B. pumilus DSM 32539 produces almost twice as much lactate compared to probiotic strain of Bacillus toyonensis.
  • Example 8 Comparison of performance of swine reared in China fed the novel Bacillus pumilus strain DSM 32539
  • the experiment comprises 186 25-day weaned piglets (Landrace x Yorkshire), randomly allocated to three treatments (Table 8.1), with 8 replicates, 7 piglets with average 6.5 ⁇ 0.5 kg for each replicate.
  • Four treatments were mainly based on corn-soybean meal (Table 8.2) and included; 1. Basal control (Control), 2. Control + 30 g of Virginiamycin/MT of feed (AGP), 3. Control + Bacillus pumilus strain DSM 32539 at 250 g/MT containing 2.0* 10 9 cfu/g (DSM 32539).
  • Experimental treatments were fed ad libitum in mash form from 1-42 days of age.
  • Diarrhea score (in percent of piglets suffering diarrhea)
  • Average daily weight gain, feed conversion ratio, feed intake as well as the diarrhea score were significantly improved by addition of the B. pumilus strain in comparison to the negative control but similar to positive control containing AGP.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Hydrology & Water Resources (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Environmental & Geological Engineering (AREA)
  • Mycology (AREA)
  • Water Supply & Treatment (AREA)
  • Physiology (AREA)
EP18733289.5A 2017-06-30 2018-06-28 Bacillus pumilus Withdrawn EP3645750A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17179034 2017-06-30
CN201710616364 2017-07-26
PCT/EP2018/067435 WO2019002476A1 (en) 2017-06-30 2018-06-28 BACILLUS PUMILUS STRAIN HAVING PROBIOTIC ACTIVITY

Publications (1)

Publication Number Publication Date
EP3645750A1 true EP3645750A1 (de) 2020-05-06

Family

ID=62705611

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18733289.5A Withdrawn EP3645750A1 (de) 2017-06-30 2018-06-28 Bacillus pumilus

Country Status (3)

Country Link
EP (1) EP3645750A1 (de)
CN (1) CN109207391A (de)
WO (1) WO2019002476A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11173184B2 (en) 2016-05-31 2021-11-16 Evonik Operations Gmbh Bacillus subtilis strain with probiotic activity
EP3794952A1 (de) * 2019-09-19 2021-03-24 DSM IP Assets B.V. Futterzusatz enthaltend bacillus stämme zur erhöhung der absorption von vitamin e
EP3878980A1 (de) 2020-03-12 2021-09-15 Waterford Institute Of Technology Isolierter bacillus-altitudinis-stamm und seine verwendung als probiotikum
CN111548965B (zh) * 2020-05-20 2022-03-18 山东省农业科学院 一株驴源短小芽孢杆菌及其在制备治疗驴驹腹泻的药物上的应用
FR3118058A1 (fr) 2020-12-22 2022-06-24 H T S Bio Souche de bacillus pumilus presentant un fort antagonisme vis-a-vis de pathogenes de surface
CN113025534B (zh) * 2021-04-26 2022-05-27 佛山市南海东方澳龙制药有限公司 一株具有较强抑菌作用的新种芽孢杆菌x901株及其应用
GB2621324A (en) * 2022-08-03 2024-02-14 Pruex Ltd Treatment of animal waste
GB2621155A (en) * 2022-08-03 2024-02-07 Pruex Ltd Treatment of animal waste

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63209580A (ja) 1987-02-25 1988-08-31 Karupisu Shokuhin Kogyo Kk バチルス・ズブチリスｃ−３１０２
CA2265471A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S Peniophora phytase
WO1998050422A1 (en) 1997-05-09 1998-11-12 Agraquest, Inc. A novel strain of bacillus for controlling plant diseases and corn rootworm
AU2003203147B2 (en) 1998-03-23 2008-05-29 Novozymes A/S Phytase variants
US6194193B1 (en) * 1998-12-11 2001-02-27 David J. Drahos Nutrient plant formulation with microbial strains
CA2356642A1 (en) 1999-01-22 2000-07-27 Novozymes A/S Improved phytases
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
US7247299B2 (en) 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US8021654B2 (en) 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains

Also Published As

Publication number Publication date
CN109207391A (zh) 2019-01-15
WO2019002476A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
JP7104078B2 (ja) プロバイオティクス活性がある枯草菌株
US20220117264A1 (en) Fermentation broths and their use
JP6991162B2 (ja) プロバイオティック活性を示すバチルス・サブティリス（Ｂａｃｉｌｌｕｓ ｓｕｂｔｉｌｉｓ）菌株
US11173184B2 (en) Bacillus subtilis strain with probiotic activity
EP3645750A1 (de) Bacillus pumilus
WO2017207371A9 (en) Bacillus licheniformis strain with probiotic activity
EP3447122A1 (de) Bacillus-subtilis-stamm mit probiotischer aktivität
WO2019038153A1 (en) DEBACILLUS SUBTILIS STRAIN HAVING PROBIOTIC ACTIVITY
JP2023123473A (ja) バシラエン産生細菌またはその調製物を含有する組成物
WO2023156218A1 (en) Bacillota strains with improved outgrowth
CN109423460A (zh) 具有益生菌活性的枯草芽孢杆菌菌株
EP4090774A1 (de) Bacillus-stämme mit fähigkeit zum abbau anorganischer stickstoffverbindungen
RU2804144C2 (ru) Композиции, содержащие бактерии, продуцирующие бациллен, или его препараты
TW201809264A (zh) 具有益生菌活性之地衣芽孢桿菌（Ｂａｃｉｌｌｕｓ ｌｉｃｈｅｎｉｆｏｒｍｉｓ）菌株
RU2810249C2 (ru) Ферментационные бульоны и их применение
WO2023011828A1 (en) Microorganisms displaying viral decoy receptors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRAIN BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRAIN BIOTECH AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240103